Remix Therapeutics appoints Nicole Sweeny as Chief Commercial Officer. Accomplished industry executive to lead commercial strategy and launch readiness. WATERTOWN, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) - Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Nicole Sweeny as Chief Commercial Officer. "As we continue to advance our pipeline and build the foundation for long-term growth, Nicole's proven track record of commercial leadership, strategic vision, and patient-centric approach make her an outstanding addition to our executive team," said Peter Smith, Ph.D., Co-Founder and CEO of Remix. "Nicole has successfully guided organizations through critical stages of growth and commercialization, and her experience will be invaluable as we work to bring transformative medicines to patients." "Remix has built a truly differentiated platform with the potential to unlock a new class of medicines by targeting RNA processing," said Ms. Sweeny. "I am excited to join the team at such an important time in the company's evolution. I look forward to working alongside my colleagues to ensure that, as our programs advance, we remain focused on delivering meaningful therapies to patients while building the capabilities needed to support future launches and sustained growth." Ms. Sweeny brings more than 20 years of commercial strategy and leadership experience launching innovative therapies across rare disease and specialty biopharma. Prior to joining Remix, she served as Chief Commercial Officer at KalVista Pharmaceuticals, where she built and led the company's commercial organization and launch readiness efforts through its acquisition by Chiesi Group. Before that, she served as Chief Commercial Officer at Praxis Precision Medicines. Earlier in her career, Ms. Sweeny was a Franchise Head in US Rare Diseases at Takeda Pharmaceuticals. Before Takeda, she held positions of increasing responsibility at Shire Pharmaceuticals in marketing, sales and product strategy. Ms. Sweeny received a B.S. in Marketing from the Carroll School of Management at Boston College. About Remix Therapeutics Remix Therapeutics is a clinical stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster(TM) technology platform leverages data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's therapeutic approach led to the discovery of REM-422, an investigational small molecule designed to modulate RNA processing in oncology, currently being evaluated in two clinical programs: the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC) and a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).

Remix Therapeutics to participate in upcoming investor conferences. WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) - Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that management will participate in the following upcoming investor conferences: * Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the 21st Annual Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at 10:15 a.m. ET in Boston. * Remix management will participate in 1x1 meetings at the Cantor Global Healthcare Conference 2026 on Wednesday, September 9, 2026, in New York City. About Remix Therapeutics Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster(TM) technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, an RNA processing modulator in oncology, now being evaluated in a Phase 1/2 clinical study to treat acute myeloid leukemia (AML), and a Phase 1 clinical study in high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC). Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Alabama Business Reporter do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Remix Therapeutics to merge with Passage Bio. On Jun 25, 2026 Remix Therapeutics and Passage Bio have agreed to merge in an all-stock transaction, creating a combined biotechnology company focused on advancing RNA-targeted therapies for cancer and other serious diseases. The deal is backed by a new $100 million private financing, providing the merged company with the resources needed to advance its clinical pipeline through several key development milestones. Following the completion of the transaction, the combined company will operate under the name Remix Therapeutics, Inc. and is expected to trade on the Nasdaq stock exchange under the ticker symbol "RMTX." Alongside the merger announcement, Remix revealed that it has secured commitments for an oversubscribed private placement financing led by Decheng Capital, with participation from Lynx1 Capital Management, Forge Life Science Partners, existing investors, and several other institutional investment firms. The financing is expected to close immediately before the merger is finalized. The combined company expects its cash position, including proceeds from the private placement, to fund operations into 2028. The funding is intended to support several important clinical milestones, including data from the registrational Phase 2 trial of REM-422 in Adenoid Cystic Carcinoma (ACC), results from a Phase 1 trial evaluating the therapy in Acute Myeloid Leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS), as well as continued investment in Remix's discovery pipeline. The merger strengthens Remix's position as it develops a new class of small-molecule medicines designed to modulate RNA processing. Unlike conventional therapies that target proteins directly, Remix's platform focuses on controlling how RNA is processed inside cells, offering the potential to treat diseases driven by genetic abnormalities that have historically been difficult to target with existing drugs. At the center of the company's pipeline is REM-422, an orally administered mRNA degrader that targets MYB, a transcription factor involved in several cancers. MYB has long been considered one of the most challenging cancer targets for drug developers, making REM-422 a potentially significant advance if ongoing clinical studies continue to produce positive results. Peter Smith, Ph.D., co-founder and Chief Executive Officer of Remix Therapeutics, described the merger as a transformative milestone for the company. He said the transaction provides the financial strength and operational support needed to accelerate the development of RNA-targeted medicines while expanding the company's proprietary platform. Smith added that the financing and merger position Remix to rapidly advance REM-422 and other pipeline candidates, with the goal of delivering innovative treatment options for patients with cancers that currently have limited therapeutic choices. For Passage Bio, the agreement follows an extensive review of strategic alternatives aimed at maximizing shareholder value. President and Chief Executive Officer Dr. Will Chou said Remix emerged as the ideal partner because of its differentiated RNA processing technology and encouraging early clinical data for REM-422 in adenoid cystic carcinoma. Chou noted that the ongoing registrational study, combined with the company's experienced leadership team, offers Passage Bio shareholders the opportunity to participate in a clinical-stage biotechnology company with a clearly defined path toward pivotal clinical data. The merger reflects growing investor confidence in RNA-based drug development, an area that has attracted increasing attention across the biotechnology industry. By combining Passage Bio's public company infrastructure with Remix's clinical-stage pipeline and fresh capital, the new organization aims to accelerate the development of innovative RNA-targeted therapies and expand treatment options for patients with difficult-to-treat cancers.